Supreme Court Rejects Bayer Appeal, Leaving Door Open for Thousands of Roundup Cancer Lawsuits

The United States Supreme Court has declined to intervene in the ongoing legal battle surrounding the weedkiller Roundup, rejecting a critical appeal by its manufacturer, Bayer AG. The German pharmaceutical and chemical conglomerate had sought to dismiss a lawsuit brought by a consumer who claimed that decades of using the glyphosate-based herbicide caused his non-Hodgkin's lymphoma. By refusing to hear the case, the nation’s highest court has effectively dealt a severe blow to Bayer’s primary legal defense, leaving the company exposed to thousands of similar active lawsuits across the country.

At the heart of Bayer’s legal strategy was the argument of federal preemption. The company contended that because the U.S. Environmental Protection Agency (EPA) has consistently approved the use of glyphosate and ruled that it does not require a cancer warning label, state-level "failure-to-warn" lawsuits should be legally preempted by federal law. However, lower courts have repeatedly rejected this defense, a stance that the Supreme Court's refusal to review now leaves intact. This legal battle has its roots in Bayer's $63 billion acquisition of Monsanto in 2018, which brought the Roundup brand—and its mounting legal liabilities—under Bayer’s corporate umbrella.

The financial ramifications of the decision are substantial for Bayer, which has struggled to reassure investors amid a depressed stock price and persistent legal uncertainty. While the company has already earmarked more than $11 billion to resolve roughly 125,000 existing Roundup claims, tens of thousands of cases remain outstanding. Following the Supreme Court's decision, Bayer will have to continue defending these cases in state courts or negotiate further multi-billion-dollar settlements. In a statement regarding the litigation, Bayer maintained that it stands behind the safety of Roundup, pointing to decades of scientific consensus and regulatory approvals supporting the safe use of glyphosate.

Key Takeaways from the Supreme Court Decision:

• Legal Precedent Unchanged: The refusal to hear the appeal means state courts can continue to hear cases arguing that Roundup’s packaging failed to warn consumers of potential cancer risks.
• Financial Strain: Analysts predict that without federal protection, Bayer may be forced to increase its litigation reserves, potentially impacting its corporate restructuring plans and stock valuation.
• Regulatory Divide: The decision highlights the ongoing tension between federal regulatory agencies like the EPA, which maintain glyphosate is safe when used as directed, and civil jury verdicts that have awarded billions of dollars to plaintiffs based on independent scientific studies.